|
BMEA | Biomea Fusion, Inc. |
| Pharmaceutical Preparations |
| Book value per $ invested | $ 0.31 |
| Leverage | 71.70% |
| Market Cap | $ 50.3m |
| PE | 0.00 |
| Dividend Yield | 0.00% |
| Profit | $ -95.5m |
| Margin | 0.00% |
Biomea Fusion, Inc., a biopharmaceutical company, is focused on the discovery, development and commercialization of irreversible small molecules to treat patients with genetically defined cancers. The company is headquartered in Redwood City, California.